AEON | AEON Biopharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.7066 - 0.8300
52 Week Range	0.7066 - 17.17
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	102,100
Average Volume	1,750,272
Shares Outstanding	39,522,200
Market Cap	30,392,572
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-07-24

Valuation
Profitability
Growth
Health
P/E Ratio	-4.52
Forward P/E Ratio	N/A
EPS	-0.17
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	10
Country	USA
Website	AEON

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

*Chart delayed

Analyzing fundamentals for AEON we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see AEON Fundamentals page.

Watching at AEON technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on AEON Technicals page.